Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEUTSCHE GELATINE FABRIKEN STEPPING IN TO STEADY SCHERER

Executive Summary

DEUTSCHE GELATINE FABRIKEN STEPPING IN TO STEADY SCHERER in the wake of the company's year-long family feud. The West German company's declared interest in the purchase of the capsule maker is the second rescue effort by the firm in a decade. Deutsche Gelatine Fabriken (DGF) disclosed in a 13-D filing with the Securities & Exchange Commission dated Feb. 6 that it has been talking to R. P. Scherer's investment banker in relation to Scherer's announced decision to consider buy-out or merger offers. DGF already owns 500,000 (or approximately 7%) of Scherer's outstanding stock. The DGF chief executive officer, Joerg Siebert, sits on the Scherer board; he is not participating in the review of merger offers. Ernst Schoepe, the current chairman of R. P. Scherer, was a managing director of DGF from 1966 to 1985. Scherer's investment banker is Goldman Sachs. The West German firm was the primary force behind the eviction of one family-led management group at Scherer in 1979. At that point, DGF was the minority partner of the company's West German affiliate. After a series of disagreements with the U.S. management group headed by R. P. Scherer, Jr., DGF sided with a new management group headed by Peter Fink, a brother-in-law to R. P. Scherer, Jr. Fink was president until being forced out in a dispute with his wife (Karla Scherer) in 1988. He has announced his intention to form an investment firm and has not ruled out an attempt to resume control of Scherer. The West German firm is stating its current intentions clearly in an apparent attempt to ward off other offers. "While DGF is maintaining its beneficial ownership of shares of common stock as an investment," the SEC filing states, "DGF plans to pursue its investigation of ]Scherer[ with the intention of making a definitive proposal to acquire all outstanding shares of common stock on a fully diluted basis." DGF declared that it has informed Goldman Sachs of its intent.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel